175137-13-0

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
3-METHYLTHIENO(3,2-D)PYRIMIDIN-7(6H)-ONE is utilized as a key building block for the synthesis of biologically active molecules, contributing to the development of new pharmaceutical agents. Its unique thieno-pyrimidinone core structure offers a versatile platform for the creation of compounds with potential therapeutic applications.
Used in Drug Discovery:
In the field of drug discovery, 3-METHYLTHIENO(3,2-D)PYRIMIDIN-7(6H)-ONE serves as a valuable starting point for the design and synthesis of novel drug candidates. Its structural features can be modified to explore a range of biological activities, enhancing the chances of identifying effective treatments for various diseases.
Used in Organic Synthesis:
3-METHYLTHIENO(3,2-D)PYRIMIDIN-7(6H)-ONE is employed as an intermediate in organic synthesis, allowing for the preparation of a variety of complex organic compounds. Its reactivity and functional group compatibility make it a useful component in the synthesis of advanced organic molecules with potential applications in various industries.
Used in Research and Development:
In the realm of research and development, 3-METHYLTHIENO(3,2-D)PYRIMIDIN-7(6H)-ONE is used as a subject for exploration to uncover its potential uses and properties. Ongoing studies aim to expand the understanding of its chemical behavior and interactions, which could lead to innovative applications in diverse fields.

InChI:InChI=1/C7H6N2OS/c1-4-2-11-6-5(4)8-3-9-7(6)10/h2-3H,1H3,(H,8,9,10)

Upstream product

• 85006-31-1 3-amino-4-methyl-2-thiophenecarboxylic acid methyl ester 
• 443762-03-6 methyl 3-formamido-4-methylthiophene-2-carboxylate 
• 77287-34-4 formamide 

Downstream Products

• 175137-21-0 4-chloro-7-methylthieno[3,2-d]pyrimidine 
• 209286-57-7 7-(bromomethyl)-4-chlorothieno[3,2-d]pyrimidine 
• 1269667-57-3 4-chlorothieno[3,2-d]pyrimidine-7-carboxylic acid 
• 1318133-05-9 4-chloro-N-(2,6-difluoro-3,5-dimethoxyphenyl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1318133-07-1 4-amino-N-(2,6-difluoro-3,5-dimethoxyphenyl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1318128-97-0 4-(cyclopropylamino)-N-(2,6-difluoro-3,5-dimethoxyphenyl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1318133-08-2 N-(4-bromo-3,5-dimethoxyphenyl)-4-chlorothieno[3,2-d]pyrimidine-7-carboxamide 
• 1318130-12-9 N-(4-bromo-2,6-dichloro-3,5-dimethoxyphenyl)-4-chlorothieno[3,2-d]pyrimidine-7-carboxamide 
• 1318131-14-4 N-(4-bromo-2,6-dichloro-3,5-dimethoxyphenyl)-4-(4-(4-ethylpiperazin-1-yl)benzamido)thieno[3,2-d]pyrimidine-7-carboxamide 
• 871013-26-2 7-methylthieno[3,2-d]pyrimidine 
• 1211596-51-8 thieno[3,2-d]pyrimidine-7-carbaldehyde 
• 1446113-41-2 7-hydroxymethylthieno[3,2-d]pyrimidine 
• 871013-27-3 C₇H₅BrN₂S 
• 1318243-03-6 N-(5-amino-2-methylphenyl)-4-(cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxamide 

Relevant academic research and scientific papers

Chemical Space Exploration around Thieno[3,2- d]pyrimidin-4(3 H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors

Clostridium difficile infection (CDI) is the leading cause of healthcare-associated infection in the United States. Therefore, development of novel treatments for CDI is a high priority. Toward this goal, we began in vitro screening of a structurally diverse in-house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-4(3H)-one (2) with moderate potency (MIC = 312/156 μM). Optimization of 2 gave lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one) with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s > 606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid. Further optimization of 6a at C2-, N3-, C4-, and C7-positions resulted in a library of >50 compounds with MICs ranging from 3 to 800 μM against clinical isolates of C. difficile. Compound 8f (MIC = 3/6 μM) was identified as a promising lead for further optimization.

Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD)

A novel thienopyrimidinone analog was discovered as a potent and highly selective TAK1 inhibitor using the SBDD approach. TAK1 plays a key role in inflammatory and immune signaling, so TAK1 is considered to be an attractive molecular target for the treatm

THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

NEW COMPOUNDS

There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.